novavax inc (NVAX) Key Developments
Novavax, Inc. Presents Data on RSV F Nanoparticle Vaccine Induced Monoclonal Antibody at ICAAC
Sep 6 14
Novavax, Inc. presented preclinical data demonstrating that antibodies generated to its RSV F-protein nanoparticle vaccine candidate (RSV F vaccine) bind to the site II epitope of the RSV F-protein with a higher affinity than palivizumab (Syangis(R)) at the 54(th) Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. In poster session 024: I-314b titled "Development and Characterization of Recombinant RSV Nanoparticle Vaccine Induced Monoclonal Antibody." [Exhibit Hall B, Saturday, September 6, 2014 from 12:00 to 2:00 pm], Novavax used its RSV F vaccine to generate a murine monoclonal antibody, NVX4C6, that binds to the antigenic site II on the RSV F-protein. Using Surface Plasmon Resonance (SPR), Novavax was able to compare the binding affinity of NVX4C6 and palivizumab to the antigenic site II. This experiment demonstrated that Novavax' RSV F vaccine can induce antibodies to the antigenic site II (specifically NVX4C6) that have a higher binding affinity to the site than palivizumab. In addition, NVX4C6 was shown to have a slightly different specificity to the site II epitope and to recognize mutated site II peptide not recognized by palivizumab, suggesting that NVX4C6 may neutralize palivizumab escape mutants.
Novavax, Inc. to Present RSV Vaccine Clinical and Preclinical Results at ICAAC
Sep 3 14
Novavax, Inc. announced that it will present data from recent preclinical studies of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Nanoparticle Vaccine) at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C., September 5-9, 2014 at the Walter E. Washington Convention Center.
Novavax, Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-03-2014
Aug 12 14
Novavax, Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-03-2014 . Venue: The Mandarin Oriental Boston, 776 Boylston Street, Boston, MA 02119, United States.
Novavax, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014
Aug 6 14
Novavax, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net loss of $17.9 million, or $0.08 per share compared to a net loss of $12.6 million, or $0.08 per share, for the second quarter of 2013. Revenue increased 134% to $8.3 million as compared to $3.5 million for the same period in 2013. The increase in revenue was primarily due to the higher level of activity in the second quarter of 2014 associated with the company's Phase 1/2 clinical trial using its H7N9 pandemic influenza candidate and Matrix-M adjuvant and preliminary manufacturing work for its Phase 2 seasonal influenza clinical trial, both under the HHS BARDA contract, and with the company's Phase 2 clinical trial in women of childbearing age under its amended collaboration with PATH. Loss from operations was $17.851 million against $12.898 million a year ago. Loss from operations before income tax expense was $17.864 million against $12.628 million a year ago.
For the six months ended June 30, 2014, net loss was $31.7 million, or $0.15 per share, compared to a net loss of $22.6 million, or $0.15 per share, for the same period in 2013. Net cash used in operating activities was $31.4 million compared to $18.2 million for the same period in 2013. Revenue was $15.721 million against $7.365 million a year ago. Loss from operations was $32.236 million against $22.902 million a year ago. Loss from operations before income tax expense was $31.674 million against $22.608 million a year ago.
Novavax, Inc. to Report Q2, 2014 Results on Aug 06, 2014
Jul 30 14
Novavax, Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 06, 2014